Diamond-Blackfan anemia medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 8: | Line 8: | ||
==Medical Therapy== | ==Medical Therapy== | ||
[[Corticosteroids]] can be used to treat anemia in DBA. In a large study of 225 patients, 82% initially responded to this therapy, although many side effects were noted.<ref>{{cite journal | author= Vlachos A, Klein GW, Lipton JM | title= The Diamond Blackfan Anemia Registry: tool for investigating the epidemiology and biology of Diamond-Blackfan anemia. | journal= J. Pediatr. Hematol. Oncol. | year=2001 | pages=377-82 | volume=23 | issue=6 | id=PMID 11563775}}</ref> Some patients remained responsive to steroids, while [[efficacy]] waned in others. | *[[Corticosteroids]] can be used to treat anemia in DBA. In a large study of 225 patients, 82% initially responded to this therapy, although many side effects were noted.<ref>{{cite journal | author= Vlachos A, Klein GW, Lipton JM | title= The Diamond Blackfan Anemia Registry: tool for investigating the epidemiology and biology of Diamond-Blackfan anemia. | journal= J. Pediatr. Hematol. Oncol. | year=2001 | pages=377-82 | volume=23 | issue=6 | id=PMID 11563775}}</ref> Some patients remained responsive to steroids, while [[efficacy]] waned in others. Individuals with DBA, especially those on corticosteroid treatment, should take reasonable precautions to avoid infections | ||
*[[Blood transfusions]] can also be used to treat severe anemia in DBA. Periods of [[remission]] may occur, during which transfusions and steroid treatments are not required. | |||
*[[Bone marrow transplantation]] (BMT) can cure hematological aspects of DBA. This option may be considered when patients become transfusion-dependent because frequent transfusions can lead to iron overloading and organ damage. However, data from a large DBA patient registry indicated that [[adverse events]] in transfusion-dependent patients were more frequently caused by BMTs than iron overloading. | |||
*Cancer treatment | |||
*[[Prevention of secondary complications]]: | |||
*Iron chelation | |||
**Deferasirox is recommended in individuals age two years or older. | |||
**Desferrioxamine | |||
*Evaluation of Relatives at Risk | |||
**Molecular genetic testing if the pathogenic variant in the family is known | |||
**Consideration of other testing (e.g., mean corpuscular volume, eADA, and/or fetal hemoglobin concentration) if the pathogenic variant in the family is not known – especially of relatives being considered as bone marrow donors | |||
==References== | ==References== | ||
Revision as of 19:58, 5 August 2020
|
Diamond-Blackfan anemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diamond-Blackfan anemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Diamond-Blackfan anemia medical therapy |
|
Risk calculators and risk factors for Diamond-Blackfan anemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
- Corticosteroids can be used to treat anemia in DBA. In a large study of 225 patients, 82% initially responded to this therapy, although many side effects were noted.[1] Some patients remained responsive to steroids, while efficacy waned in others. Individuals with DBA, especially those on corticosteroid treatment, should take reasonable precautions to avoid infections
- Blood transfusions can also be used to treat severe anemia in DBA. Periods of remission may occur, during which transfusions and steroid treatments are not required.
- Bone marrow transplantation (BMT) can cure hematological aspects of DBA. This option may be considered when patients become transfusion-dependent because frequent transfusions can lead to iron overloading and organ damage. However, data from a large DBA patient registry indicated that adverse events in transfusion-dependent patients were more frequently caused by BMTs than iron overloading.
- Cancer treatment
- Prevention of secondary complications:
- Iron chelation
- Deferasirox is recommended in individuals age two years or older.
- Desferrioxamine
- Evaluation of Relatives at Risk
- Molecular genetic testing if the pathogenic variant in the family is known
- Consideration of other testing (e.g., mean corpuscular volume, eADA, and/or fetal hemoglobin concentration) if the pathogenic variant in the family is not known – especially of relatives being considered as bone marrow donors
References
- ↑ Vlachos A, Klein GW, Lipton JM (2001). "The Diamond Blackfan Anemia Registry: tool for investigating the epidemiology and biology of Diamond-Blackfan anemia". J. Pediatr. Hematol. Oncol. 23 (6): 377–82. PMID 11563775.